Healthcare / Medical DevicesNasdaqGM
$3.50
+0.44 (+14.38%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-38.5M · quality 73.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
27/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$165M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-36.2%
↓Gross Margin
46.7%
↓Debt/Equity
0.13
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2016–2025 · 9 años de histórico normalizado
Revenue CAGR
+25.8%
FCF CAGR
—
FCF margin
-57.6%
FCF / Net income
0.75x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $138.7M · net income $-107.2M · FCF $-79.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | $138.7M | $138.7M | $135.4M | $121.1M | $105.0M | $110.6M | $86.4M | $56.7M | $37.6M | $22.9M | $17.6M |
| Net Income | $-107.2M | $-107.2M | $-38.5M | $-28.4M | $-99.6M | $-55.5M | $-31.5M | $-40.8M | $-31.5M | $-27.0M | $-23.2M |
| EBITDA | $-90.9M | $-90.9M | $-44.3M | $-36.4M | $-68.6M | $-51.6M | $-27.3M | $-38.6M | $-30.2M | $-25.5M | $-21.3M |
| EPS | -2.51 | -2.51 | -1.00 | -0.75 | -2.61 | -1.54 | -1.07 | -1.63 | — | — | — |
| Gross Margin | 46.7% | 46.7% | 59.9% | 60.3% | 42.7% | 58.6% | 55.8% | 47.3% | 47.7% | 43.7% | 44.1% |
| Operating Margin | -79.2% | -79.2% | -38.8% | -36.9% | -71.2% | -51.1% | -36.6% | -73.3% | -83.8% | -113.7% | -123.5% |
| Net Margin | -77.3% | -77.3% | -28.4% | -23.4% | -94.9% | -50.2% | -36.5% | -71.9% | -83.8% | -118.1% | -131.8% |
| Balance Sheet | |||||||||||
| Debt/Equity | 0.13 | 0.13 | 0.11 | 0.12 | 0.12 | — | 0.04 | 0.06 | 0.19 | 0.07 | — |
| Current Ratio | 3.72 | 3.72 | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||
| Free Cash Flow | $-79.8M | $-79.8M | $-38.5M | $-22.7M | $-60.2M | $-61.3M | $-27.3M | $-37.0M | $-30.2M | $-23.2M | $-18.3M |
| Returns | |||||||||||
| ROE | -36.2% | -36.2% | -11.7% | -8.1% | -27.8% | -12.5% | -15.3% | -31.7% | -76.8% | -41.0% | 20.1% |
| Valuation | |||||||||||
| P/B | 0.50 | 0.50 | 1.40 | 2.75 | 1.34 | — | — | — | — | — | — |
| Growth & Yield | |||||||||||
| Revenue Growth | 2.4% | 2.4% | 11.8% | 15.4% | — | 28.0% | 52.2% | 50.8% | 64.5% | 30.1% | — |
| EPS Growth | -151.0% | -151.0% | -33.3% | 71.3% | — | -43.9% | 34.4% | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-32.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.00 → -2.51
Residual
-32.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.